Q&A with TransCelerate’s new CEO Janice Chang: Bringing the trial infrastructure to patients

TransCelerate Biopharma is unique in the nonprofit space because it brings together more than 20 top pharma competitors and allows them to collaborate, rather than compete, on common R&D pain points.

Helping to build this collaborative environment is TransCelerate’s new CEO Janice Chang, who moved into her new role in January after serving as COO for more than a decade.

Chang sat down with Endpoints News for an in-person interview at the DIA conference in Boston on Wednesday. Below is a lightly edited version of that conversation.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

What the brains of song birds can teach us about human stuttering

A symphony of synapses fires every time a songbird sings. For Erich Jarvis, a neurobiologist at Rockefeller University, the neural pathways he finds particularly interesting

March 15, 2024

Pre-pregnancy weight loss surgery type may affect child’s early weight gain

The type of weight loss surgery women undergo before becoming pregnant may affect how much weight their children gain in the first three years of

June 3, 2024

Commure’s latest acquisition sends follow-up texts to patients

General Catalyst-backed Commure is buying another General Catalyst-backed startup that sends follow-up texts to patients. Commure, which was valued at over … Sign up to

December 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.